CBD recognizes enormous opportunities at the interface of these cargo classifications. For example, combination of small molecule encapsulation with antibodies provide opportunities in developing innovative and impactful alternates to antibody-drug conjugates (ADCs) (Bioconjugate Chem. 2015, 26, 2198–2215). Similarly, combining the delivery of proteins and nucleic acids present opportunities in novel cell-based therapies, including in genome editing strategies such TALEN and CRISPR. CBD investigators are collaboratively targeting these opportunities at the interface of different technology platforms and cargoes.
Combinations And Interfaces - Faculty
There are no researchers currently for this Research Theme.
